Precision freezing targets prostate cancer, spares healthy tissue
NCT ID NCT05454488
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether freezing only the part of the prostate that contains cancer (focal cryotherapy) can control intermediate-risk prostate cancer. About 30 men with a single area of cancer will receive this targeted treatment. The goal is to reduce side effects while keeping the cancer in check.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERMEDIATE RISK PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?